Fluxion Biosciences Announces Collaboration with Stanford University School of Medicine for Circulating Tumor Cell …

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Fluxion Biosciences, Inc. announced today that it has initiated a collaboration with the Stanford University School of Medicine focused on developing tests to help deliver more effective therapies to cancer patients. The laboratory of Dr. Stefanie Jeffrey is utilizing Fluxions IsoFlux System to isolate, recover, and analyze rare circulating cancer cells at the molecular level.

Circulating tumor cells disseminate from primary tumors and enter the peripheral bloodstream. These cells have been shown to contribute to the metastatic process in carcinomas such as breast, prostate, colorectal, lung, and pancreatic cancer. Using the unique molecular signatures of each cancer patients disease status, a new generation of personalized cancer therapies is emerging. Access to cancer tissue represents one of the most significant challenges in characterizing cancer. Tests that utilize minimally-invasive blood draws will play a pivotal role in identifying these molecular profiles and how they change over time. The IsoFlux System provides a real-time liquid biopsy that delivers high quality samples optimized for molecular analysis. The IsoFlux System installed in Dr. Jeffreys laboratory targets a number of applications, including mutational analysis and cancer cell culturing, in collaboration with Visiting Professor, Dr. Shanaz Dairkee.

The IsoFlux System utilizes a proprietary microfluidic technology to isolate rare cells with high efficiency. Samples coming from the IsoFlux System are immediately ready for downstream analysis. A variety of analytical techniques are available for isolated cell samples such as mutation detection, gene expression, sequencing, and protein analysis.

The collaboration with Stanford will focus on breast and lung cancer pathologies. The research is designed to help subtype different forms of the disease and develop more effective treatments tailored to each patient. We are very excited to be working with Dr. Jeffrey on this project, commented Michael Schwartz, Program Director at Fluxion. She is widely respected as a leader in the field of personalized cancer therapies, and is backed by the support of a world-class medical institution at Stanford.

For more information about the IsoFlux System, or to participate in the Early Access Program, please visit http://www.fluxionbio.com/products/isoflux-rare-cell-access/.

About Fluxion Biosciences

Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Fluxions proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Products include the BioFlux System for studying cellular interactions, the IonFlux System for automated ion channel testing, and the IsoFlux System for circulating tumor cell access. Fluxions systems meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use operating system for single-cell biology. For more information about Fluxion Biosciences, visit http://www.fluxionbio.com.

Read the original here:
Fluxion Biosciences Announces Collaboration with Stanford University School of Medicine for Circulating Tumor Cell ...